See more : Jerónimo Martins, SGPS, S.A. (JRONY) Income Statement Analysis – Financial Results
Complete financial analysis of ZyVersa Therapeutics, Inc. (ZVSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ZyVersa Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Brunswick Corporation 6.500% Se (BC-PA) Income Statement Analysis – Financial Results
- Rich Circle Development Co., Ltd. (6198.TWO) Income Statement Analysis – Financial Results
- Electreon Wireless Ltd (ELWSF) Income Statement Analysis – Financial Results
- Allied Copper Corp. (CPR.V) Income Statement Analysis – Financial Results
- Jammin Java Corp. (JAMN) Income Statement Analysis – Financial Results
ZyVersa Therapeutics, Inc. (ZVSA)
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 10.40K | 10.40K | 10.40K | 10.40K |
| Gross Profit | -10.40K | -10.40K | -10.40K | -10.40K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.21M | 5.41M | 2.12M | 6.47M |
| General & Administrative | 11.21B | 7.61M | 5.58M | 5.36M |
| Selling & Marketing | -11.20B | 0.00 | 0.00 | 0.00 |
| SG&A | 11.20M | 7.61M | 5.58M | 5.36M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.41M | 13.01M | 7.70M | 11.83M |
| Cost & Expenses | 14.42M | 13.01M | 7.70M | 11.83M |
| Interest Income | 0.00 | 427.54 | 821.37 | 516.45 |
| Interest Expense | -457.00K | 427.54K | 821.37K | 516.45K |
| Depreciation & Amortization | 10.40K | 10.40K | 10.40K | 10.40K |
| EBITDA | -107.74M | -11.67M | -7.25M | -12.16M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -14.42M | -13.01M | -7.70M | -11.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -93.33M | -2.37M | -379.79K | -850.11K |
| Income Before Tax | -107.75M | -14.05M | -8.08M | -12.68M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -9.46M | 745.05M | 821.37K | 516.45K |
| Net Income | -98.30M | -759.10M | -8.91M | -13.20M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.09K | -930.25 | -173.66 | -272.45 |
| EPS Diluted | -1.09K | -930.25 | -173.66 | -272.45 |
| Weighted Avg Shares Out | 97.50K | 25.95K | 46.55K | 46.55K |
| Weighted Avg Shares Out (Dil) | 97.50K | 25.95K | 46.55K | 46.55K |
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024
Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases.
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
WESTON, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases with high unmet medical needs, announces that on...
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
In obesity, inflammasome activation in fat tissue triggers cell death and release of inflammatory cytokines & ASC Specks, spreading damaging inflammation.
Should You Sell Your Penny Stocks? 3 Tips for When to Sell
Investing in penny stocks offers a unique opportunity for investors looking to expand their portfolios with potentially high-reward options. Recognized for their affordability, these stocks allow individuals to purchase shares in emerging companies without a significant financial outlay.
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today?
ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is rocketing higher on Monday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. ZVA stock is seeing a lot of activity this morning with more than 12.4 million shares changing hands as of...
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
Neurological diseases, which affect up to 16 million people over 18 years old in the US, are the leading cause of physical and cognitive disability. A growing body of evidence supports that activation of more than one type of inflammasome...
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
Inflammation resulting from activation of more than one type inflammasome and ASC specks contribute to development and progression of neurological disease
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones
ZyVersa CEO will discuss development milestones for Cholesterol Efflux Mediator VAR 200 and Inflammasome ASC Inhibitor IC 100 at BIO CEO & Investor Conf.
ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes
NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications (e.g., Type 2 Diabetes, Hypertension, Heart Disease).
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer's Disease
Research demonstrated that activation of the inflammasome/ASC speck pathway has a vital role in synaptic degeneration in Alzheimer's Disease (AD). ZyVersa is developing IC 100, a monoclonal antibody targeting inflammasome ASC specks to block initiation and perpetuation of damaging inflammation...
Source: https://incomestatements.info
Category: Stock Reports
What were ZyVersa’s Q3 2024 net losses?
Net losses were approximately $2.4 million for the three months ended September 30, 2024, with an improvement of approximately $0.5 million or 17.3% compared to a net loss of approximately $2.9 million for the three months ended September 30, 2023.